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Increased activity of the tumour suppressor p53 is incompatible with embryogenesis, but how
p53 is controlled is not fully understood. Differential requirements for p53 inhibitors
Mdm2 and Mdm4 during development suggest that these control mechanisms are
context-dependent. Artery formation requires investment of nascent endothelial tubes by
smooth muscle cells (SMCs). Here, we ﬁnd that embryos lacking SMC b-catenin suffer
impaired arterial maturation and die by E12.5, with increased vascular wall p53 activity.
b-Catenin-deﬁcient SMCs show no change in p53 levels, but greater p53 acetylation and
activity, plus impaired growth and survival. In vivo, SMC p53 inactivation suppresses
phenotypes caused by loss of b-catenin. Mechanistically, b-catenin C-terminal interactions
inhibit Creb-binding protein-dependent p53 acetylation and p53 transcriptional activity,
and are required for artery formation. Thus in SMCs, the b-catenin C-terminus indirectly
represses p53, and this function is essential for embryogenesis. These ﬁndings have
implications for angiogenesis, tissue engineering and vascular disease.
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T
he p53 tumour suppressor plays a fundamental role in cell
biology by inducing cell cycle arrest and apoptosis.
Increased p53 activity is incompatible with normal
embryogenesis, a process characterized by active growth. Indeed,
inactivation of the key inhibitors of p53, Mdm2 and Mdm4,
causes embryonic lethality1,2, and increased p53 activity during
development yields a phenotype resembling CHARGE
syndrome3. Although Mdm2 and Mdm4 are the major p53
inhibitors4, the differential requirement for Mdm2 and Mdm4 in
cardiac and central nervous system development5 raises the
possibility that cell type-speciﬁc mechanisms restrain p53 during
embryogenesis. This is especially intriguing during artery
formation: although smooth muscle cells (SMCs) constitute the
main component of the arterial wall, requirements for Mdm2 or
Mdm4 have not been evaluated in this cell type, and how SMCs
repress p53 function to proliferate, survive and build the arterial
wall is unknown.
Development of a competent vasculature reﬂects the
integration of several processes, including vasculogenesis,
angiogenesis, remodelling and vascular maturation. Despite
recent advances in this area6, understanding of vascular
maturation remains limited. Mural cells—SMCs in large vessels
or pericytes in the microcirculation—surround nascent
endothelial tubes in a process called investment7 to provide
quiescence and stability8, and proliferate and synthesize
extracellular matrix components to build a multilayered wall9,
but how these activities are regulated is only partly understood.
b-Catenin, the non-redundant component of the canonical
Wnt signalling pathway and structural element of the
cadherin–catenin cell-adhesion complex10, has critical functions
in embryogenesis and adult homoeostasis11. In the vasculature,
endothelial cell b-catenin is required for angiogenesis in the
central nervous system and contributes to endothelial arterial
speciﬁcation12,13. b-Catenin is also necessary for smooth muscle
development in the lung14 and in the proepicardium for coronary
artery formation15. While b-catenin promotes proliferation and
survival of cultured SMCs, and its expression and activity
are induced in adult arteries during vascular remodelling16–19,
whether it is required for vascular maturation during
development is unknown.
To address this question, we inactivated b-catenin selectively in
SMCs and tested a series of b-catenin mutants in vivo, and found
an absolute requirement for SMC b-catenin in artery formation
and mouse embryogenesis. Here, we provide evidence that
b-catenin signalling in SMCs is essential for artery formation.
Loss of this activity, particularly that emanating from the
b-catenin C-terminal interaction domain, results in an incompe-
tent circulation that cannot support embryogenesis. Interestingly,
b-catenin performs this function in part by inhibiting p53
activity.
Results
SMC b-catenin is essential for artery formation. We studied
SMC-selective inactivation of Ctnnb1 (b-catenin) by crossing
Tagln-Cre transgenic20 and Ctnnb1ﬂox/ﬂox mice21. We found no
surviving Tagln-Cre;Ctnnb1ﬂox/ﬂox (SMbCKO; see Table 1 for
mouse line abbreviations) progeny at E13.5 or beyond (Fig. 1a;
Supplementary Tables 1 and 2; Supplementary Fig. 1a,b). At
E12.5, all control embryos looked normal, while all SMbCKO
embryos were compromised, ranging in appearance from early
stages—small size, dilated blood vessels and compromised
overall development, but retaining recognizable morphologic
features (Fig. 1b)—to advanced stages of resorption—still
smaller, generally round and pale in appearance, and lacking
morphological features. Mutant embryos appeared grossly
normal until E10.5, indicating that vasculogenesis and early
angiogenesis were largely unaffected. Evaluation of SMbCKO
embryos revealed reduced wall thickness of the paired and fused
dorsal aortas (PDA and FDA, respectively) as early as E10.5
(Fig. 1c–e), plus increased cross-sectional area of the FDA at
E11.5 (Fig. 1c,f); immunohistochemistry conﬁrmed decreased
b-catenin expression in the vessel wall and heart (Supplementary
Fig. 1c). Because Tagln is transiently expressed in the heart,
we also looked for a potential cardiac phenotype, but did not ﬁnd
(1) signs of cardiac dysfunction, such as oedema or pericardial
effusion (Supplementary Fig. 1d), (2) differences in the future left
or right ventricles, compact or trabeculated myocardium
(Supplementary Fig. 1e–g), (3) change in outﬂow tract (OT)
dimensions in SMbCKO embryos at E10.5 (Supplementary
Fig. 1h) or (4) major structural abnormalities at E11.5
(Supplementary Fig. 1i)—these observations differ from a
report of b-catenin inactivation using a different Tagln-Cre
transgenic line, which describes severe right ventricular
hypoplasia at E9.5 and demise between E10.5 and E11.5
(ref. 22). In our system, possibly due to different transgene
integration site or modest variation in level, timing or distribution
of Tagln-Cre expression or strain background, we observe that
b-catenin loss in SMCs impairs artery formation, as reﬂected by
thinned and dilated major vessels observed before any evident
cardiac abnormality.
b-catenin promotes arterial SMC proliferation and survival.
The arterial wall has two main cellular components: endothelial
cells and SMCs. While CD31 staining demonstrated an intact
endothelial monolayer in both control and SMbCKO embryos
(Fig. 2a; Supplementary Fig. 2a), staining for SMC markers
showed lack of SMC investment and absence of a multilayered
wall by E12.5 in SMbCKO embryos (Fig. 2b). We examined
SMC-speciﬁc proliferation in the PDA wall by co-staining two
markers of proliferation, phospho-histone H3 (pHH3) or Ki67,
with smooth muscle a-actin (a-SMA), and found reduced SMC
proliferation in SMbCKOs at E9.5 and E10.5 (Fig. 2c,d;
Supplementary Fig. 2b). We also observed decreased cell pro-
liferation in the FDA wall from E9.5 to E11.5 (Supplementary
Fig. 2c). In addition, by both TUNEL assay and co-staining of
cleaved Caspase 3 and a-SMA, we observed increased SMC
apoptosis in the SMbCKO arterial wall (Fig. 2e,f; Supplementary
Fig. 2d). These ﬁndings suggest that the necessity for SMC
b-catenin in formation of a multilayered arterial wall stems from
its positive effects on cell proliferation and survival.
b-catenin is required for SMC population growth. To evaluate
how b-catenin affects basic cell functions, we isolated aortic
SMCs from Ctnnb1ﬂox/ﬂox mice and transduced them with
Cre- or GFP-expressing adenovirus to obtain b-catenin-deﬁcient
and control SMCs, respectively (Fig. 3a). In culture, SMCs lacking
b-catenin grew more slowly and plateaued at a lower density
(Fig. 3b). Moreover, with serum starvation, the b-catenin-
deﬁcient cell population decreased faster and to a greater extent
(Fig. 3c). Cell cycle analyses found more b-catenin-deﬁcient
SMCs in the G0/G1 phase and less in S or G2/M (Fig. 3d),
indicating that b-catenin is required for cell cycle progression.
Serum deprivation caused more death of b-catenin-deﬁcient than
control cells (Fig. 3e), showing that SMC b-catenin is a pro-
survival factor. On the other hand, SMC marker gene expression
and transwell cell migration were not affected by b-catenin loss,
suggesting a lack of effect on maintenance of SMC differentiation
and motility (Fig. 3f,g; Supplementary Fig. 3).
b-catenin opposes p53 acetylation and activity in SMCs.
Cdkn1a (p21) repression and Ccnd1 (cyclin D1) induction have
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms12389
2 NATURE COMMUNICATIONS | 7:12389 | DOI: 10.1038/ncomms12389 | www.nature.com/naturecommunications
been associated with activation of b-catenin/TCF signalling and
proliferation in cultured SMCs17,18, so we tested expression of
these genes, as well as that of proapoptotic Bax and antiapoptotic
Bcl2l1, which have been related to b-catenin23,24. b-Catenin-
deﬁcient SMCs expressed higher mRNA levels of Cdkn1a, Ccnd1,
Bax, and Bcl2l1, but lower levels of Axin2, a known target of
b-catenin (Fig. 4a). Since increased Ccnd1 and Bcl2l1 levels could
not explain the observed phenotype, we focused on Cdkn1a and
Bax (direct targets of p53), and hypothesized that b-catenin
might restrain p53 function to promote SMC survival and
proliferation. Using a p53 reporter assay25, we found a
substantially higher p53 transcriptional activity in b-catenin-
deﬁcient SMCs (Fig. 4b; Supplementary Fig. 4a)—importantly,
WT SMCs treated with the same Ad-Cre protocol did not exhibit
increased p53 activity (Supplementary Fig. 4b). Restoration of
b-catenin function in b-catenin-deﬁcient SMCs with b-cateninS33Y,
a constitutively active form26, reduced p53 activity toward control
levels (Fig. 4b); b-cateninS33Y also abrogated p53 activity induced
by p53 overexpression (Fig. 4c). In addition, SMCs treated
with the b-catenin inhibitor XAV939 (ref. 27), which reduced
b-catenin/TCF transcriptional activity in SMCs (Supplementary
Fig. 4c), showed an increase in p53 activity (Fig. 4d). These
observations indicate that b-catenin inhibits p53 activity in
vascular SMCs.
P53 activation involves three steps, (1) stress-induced p53
accumulation by several mechanisms, many of which affect the
ability of Mdm2 to ubiquitinate p53, (2) release of p53 from the
Mdm2- and Mdm4-mediated repression, and (3) recruitment and
interaction with numerous cofactors4. Surprisingly, b-catenin
loss in SMCs neither increased p53 expression (Fig. 4e;
Supplementary Fig. 4d), nor decreased the levels of Mdm2 and
Mdm4 (Fig. 4e). Moreover, RO-5963—an Mdm2 and Mdm4
inhibitor28, at a dose sufﬁcient to abrogate exogenous Mdm2
function in SMCs (Supplementary Fig. 4e)—did not increase p53
function in SMCs expressing physiologic levels of these ubiquitin
ligases (Fig. 4f). Similarly, siRNA-mediated knockdown of Mdm2
Table 1 | Mouse genotype abbreviations.
Genotype Abbreviation b-Catenin protein expressed in SMCs in vivo
Tagln-Cre;Ctnnb1ﬂox/ﬂox SMbCKO None
Tagln-Cre;Ctnnb1dm/ﬂox SMbCdm Only b-catenindm
Tagln-Cre;Ctnnb1D164A/ﬂox SMbCD164A Only b-cateninD164A
Tagln-Cre;Ctnnb1DC/ﬂox SMbCDC Only b-cateninDC
Tagln-Cre;Trp53ﬂox/ﬂox SMp53KO WT
Tagln-Cre;Trp53ﬂox/ﬂox;Ctnnb1ﬂox/ﬂox SMp53KO;bCKO None
Tagln-Cre;Trp53ﬂox/WT;Ctnnb1ﬂox/ﬂox SMp53þ / ;bCKO None
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Figure 1 | SMC b-catenin is essential for embryonic survival and artery formation. (a) Observed frequency of SMbCKO embryos. The red line indicates
the expected frequency. No SMbCKO were found at embryonic stage (E) 13.5 or beyond. (b) Mouse embryos at E 12.5. Arrows indicate enlarged blood
vessels. Scale bar, 1mm (c) Hematoxylin and eosin-stained sections of the PDA and FDA. Arrowheads indicate the vessel wall. Scale bar, 50mm.
(d,e) Quantiﬁcation of wall thickness of the PDA (n¼8 in every group) and FDA (n¼4 in every group). ****Po0.0001; *Po0.05. (f) Quantiﬁcation of the
cross-section area of the FDA (n¼4 in every group). ***Po0.001. In d–f, data represent the mean±s.e.m., groups were compared by two-way ANOVA
and Bonferroni’s multiple comparisons test.
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and Mdm4 in SMCs failed to induce p53 activity (Supplementary
Fig. 4f,g), which suggests that cultured SMCs do not require
Mdm2/Mdm4 to restrain p53 activity.
These observations support the idea that b-catenin inhibits
SMC p53 activity by a mechanism independent of effects on
Mdm2 and Mdm4. Conceivably, this mechanism could limit p53
binding to DNA or decrease its recruitment of transcriptional
coactivators. To separate these functions, we used a Gal4-binding
domain-p53 fusion protein (Gal4BD-p53), and found that activity
of this protein on a promoter driven via Gal4 response elements
(pFR-Luc) was greater in b-catenin-deﬁcient SMCs (Fig. 4g).
Thus, b-catenin decreases p53 transcriptional activity through a
post-translational mechanism that may affect recruitment of
transcriptional coactivators. Acetylation of p53 is indispensable
for its transcriptional activity, triggering recruitment of coactiva-
tors, among other functions29–31, so we assessed this modiﬁcation
in SMCs and found that b-catenin loss, but not Mdm2/Mdm4
inhibition, robustly increased p53 acetylation (Fig. 4h,i).
Altogether, our ﬁndings support the idea that b-catenin
indirectly inhibits p53 transcriptional activity in vascular SMCs
not by limiting its abundance or potentiating Mdm2-/Mdm4-
mediated repression, but through preventing p53 acetylation.
b-catenin restrains p53 in SMCs during artery formation. To
evaluate p53 activity in vivo, we tested SMC expression of a
known p53 target gene, Bax, in E11.5 embryos, and found that
SMbCKO embryos exhibited higher expression than controls
(Fig. 5a), consistent with increased p53 activity on loss of
b-catenin. Thus, we hypothesized that repression of p53 is an
essential aspect of the requirement for b-catenin in SMCs during
artery formation. To test this idea, we studied mice with
SM-selective inactivation of Trp53 (SMp53KO mice), and with
simultaneous inactivation of Trp53 and Ctnnb1 (SMp53KO;
bCKO). SMp53KO mice developed normally (not shown),
indicating that SMC p53 activity is not required for artery
formation. To test if unrestrained p53 activity contributes to the
phenotype seen with loss of SMC b-catenin, we compared
SMbCKO and SMp53KO;bCKO embryos at E12.5, and noted
differences in the degree of resorption. Among SMbCKO
embryos, 21% were in an early stage of resorption, while 79%
appeared advanced (Fig. 5b,c). Interestingly, development of
SMp53KO;bCKO embryos was less affected: 23% looked normal,
36% were in early resorption and only 41% in advanced
resorption—a clear difference from ﬁndings with SMbCKO
embryos (Fig. 5b,c). Moreover, in SMp53KO;bCKO embryos,
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Figure 2 | b-Catenin promotes SMC proliferation and survival during artery formation. (a) Immunohistochemistry (IHC) for the endothelial marker
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we observed aortas with multilayered walls, an observation not
seen in any SMbCKO embryos at this stage (Fig. 5d), and with
reduced Bax expression (Supplementary Fig. 5a–c). Thus loss of
SMC p53 itself has no repercussion on vascular development, but
suppresses the vascular phenotype resulting from inactivation of
SMC b-catenin, supporting the idea that b-catenin represses p53
activity in SMCs in vivo during artery formation.
In addition, SMp53þ / ;bCKO embryos phenocopied the
SMbCKO embryos (Fig. 5c,e), indicating that a single Trp53
allele provides sufﬁcient p53 activity to prevent artery formation
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on loss of SMC b-catenin, and suggesting that low levels of p53
are effective in SMCs. Although the improvement in artery
formation and overall development was important, p53 loss did
not fully overcome the phenotype of SMbCKO embryos—thus,
the critical requirement for SMC b-catenin during development
extends beyond its suppression of p53 activity.
SMC b-catenin C-terminal interactions inhibit p53 activity.
Since b-catenin has two major functions in the cell—as a
structural component in cadherin-mediated cell adhesion, and as
a signalling factor acting as a transcriptional coactivator in the
canonical Wnt pathway10—we wanted to know which function
was required for p53 regulation. We recently developed and
validated b-catenin mutants that partially or totally lack
transcriptional activity, but have intact cell-adhesion function32:
(1) Ctnnb1D164A, which has a single amino acid change (D164A)
in the ﬁrst armadillo repeat that prevents binding to the
N-terminal coactivator B-cell lymphoma 9/BCL9L, and exhibits
decreased transcriptional activity; (2) Ctnnb1DC, a C-terminal
truncation that changes codon 673 to a premature stop signal,
abrogating interaction with several C-terminal interacting
coactivators, and shows decreased transcriptional activity; and
(3) Ctnnb1dm, a double-mutant with both the D164A mutation
and the C-terminal truncation, which lacks any detectable
transcription-inducing activity (Fig. 6a). As above, we studied
these signalling-speciﬁc mutations in vascular SMCs in the
context of constitutively active b-cateninS33Y.
b-Catenindm did not repress p53 transcriptional activity
(Fig. 6b), suggesting that b-catenin signalling function is essential,
while its cell-adhesion role is not sufﬁcient to restrain p53
activity. Signalling through b-catenin depends on protein–protein
interactions with coactivators recruited by its N-terminal
and C-terminal domains10,33. We used b-cateninD164A and
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b-cateninDC to compare the importance of N- or C-terminal
interactions for p53 regulation. Similar to b-catenindm,
b-cateninDC failed to reduce p53 activity, whereas b-cateninD164A
abrogated it (Fig. 6b). Moreover, while Gal4BD-p53 transcript-
ional activity was not affected by b-catenindm or b-cateninDC,
a decrease was observed with b-cateninD164A (Fig. 6c). These
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observations suggest that b-catenin C-terminal interactions are
required to repress p53 activity in vascular SMCs, whereas
N-terminal interactions are dispensable.
Moreover, the fact that b-catenindm—which has an intact
TCF-binding domain10,32—did not repress p53 activity also
suggests that b-catenin/TCF interaction is not sufﬁcient to fulﬁl
this repressive function. To test this idea further, we used an
inhibitor of the b-catenin/TCF complex, PKF118-310 (ref. 34). A
dose of PKF118-310 that reduced b-catenin/TCF transcriptional
activity in SMCs (Supplementary Fig. 6a) did not increase p53
activity in these cells expressing endogenous or induced levels of
p53 (Supplementary Fig. 6b). Similarly, PKF118-310 decreased,
rather than increased, Gal4BD-p53 activity (Supplementary
Fig. 6c), suggesting that b-catenin/TCF interaction and
associated Wnt target genes are not acting to restrain p53
activity in vascular SMCs.
Altogether these observations support the idea that b-catenin
C-terminal interactions are necessary to restrain p53 activity
through a b-catenin/TCF-independent mechanism. Interestingly,
one of the known C-terminal interactors is the histone
acetyltransferase Creb-binding protein (CBP)10,35, which also
acetylates p53 (refs 29,36). b-Catenin prevents p53 acetylation
(Fig. 4h), so it is possible that b-catenin/CBP interaction limits
CBP availability for interaction with and acetylation of p53 in the
nucleus of vascular SMCs. Consistent with this idea, we found
that both b-catenin and CBP localized to the nucleus of SMCs by
immunoﬂuorescence (Fig. 6d) and were present in the nuclear
fraction of SMCs (Fig. 6e), and nuclear b-catenin expression was
also observed in the wall of aortas of E12.5 control embryos
(Supplementary Fig. 6d–f). Notably, blocking b-catenin/CBP
interaction with ICG001 (ref. 37), which inhibited b-catenin/TCF
transcriptional activity in SMCs (Supplementary Fig. 6g),
increased p53 acetylation (Fig. 6f); moreover, knocking down
CBP in b-catenin-deﬁcient SMCs decreased acetylation of p53
(Fig. 6g,h)—while CBP knockdown in control SMCs (Ad-GFP)
did not have any effect on their relatively low levels of acetylated
p53 (Supplementary Fig. 6h).
b-Catenin C-terminal interactions promote artery formation.
To test the physiologic relevance of the above ﬁndings, we used
mice in which mutant Ctnnb1 alleles32, like those described
above, provided the only source of b-catenin in SMCs.
We crossed Ctnnb1dm/ﬂox and Tagln-Cre;Ctnnb1ﬂox/WT mice
to produce SMbCdm (SMC b-catenin replaced with the
signalling-defective mutant), SMbCKO (complete loss of SMC
b-catenin) and Ctnnb1ﬂox/WT (wild-type b-catenin) littermates.
Interestingly, we found no SMbCdm mice in postnatal screening
(Supplementary Table 3, Supplementary Fig. 7a), indicating that
these mutants were embryonic lethal.
Notably, all E12.5 SMbCdm embryos were undergoing
resorption—with 9% early and 91% advanced in their state of
resorption. This ﬁnding was like that seen with SMbCKO
embryos (Fig. 7a,b), and indicates that b-catenin’s cell-adhesion
function in SMCs is insufﬁcient, whereas its signalling function is
essential, for artery formation and normal embryogenesis.
To evaluate the importance of N- and C-terminal SMC
b-catenin interactions in vivo, we designed breeding strategies to
produce SMbCD164A and SMbCDC mice. In postnatal screening,
these strategies yielded no SMbCDC mice (Supplementary Table 4,
Supplementary Fig. 7a), but normal appearing SMbCD164A mice
(Supplementary Table 5, Supplementary Fig. 7a) that reached
adulthood. At E12.5, 19% of SMbCDC embryos looked normal,
44% were in early resorption and 37% in advanced resorption—a
proﬁle somewhat milder than that of SMbCKO embryos (Fig. 7b).
In contrast, all SMbCD164A embryos appeared normal (Fig. 7b).
Moreover, we found correlation between whole embryo pheno-
type and the structure of the FDA at E12.5: control embryos had a
clear multilayered vessel wall, whereas SMbCKO aortas lacked
SMC investment, as described before. In some SMbCDC embryos,
we observed an important, although incomplete, recovery of the
vessel wall, while in the SMbCD164A embryos, the aortic wall was
fully restored (Fig. 7c). Since SMbCDC embryos were embryonic
lethal, but showed an intermediate phenotype at E12.5, we tested
the idea that SMbCDC could delay demise. At E15.5, a stage at
which SMbCKO embryos were never observed, we found some
SMbCDC embryos, although all of them were undergoing
resorption (Fig. 7d,e). These ﬁndings indicate that expression of
the Ctnnb1DC allele as the only source of b-catenin in SMCs
ameliorates defective artery formation and delays embryonic
death. On the other hand, Ctnnb1D164A was sufﬁcient for artery
formation that supported embryonic and postnatal development
in a proportion of mice; however, that proportion of SMbCD164A
mice observed in postnatal screening was lower than expected
(Supplementary Fig. 7b). At E15.5, stage at which all SMbCDC
embryos were abnormal, all SMbCD164A embryos looked
normal (Supplementary Fig. 7c), suggesting that demise of some
SMbCD164A mice may occur perinatally or postnatally.
Altogether, these in vivo studies support the idea that b-catenin
signalling function in SMCs is essential for artery formation.
Moreover, b-catenin C-terminal interactions are required to fulﬁl
this signalling role; by comparison, b-catenin N-terminal
interactions are not essential for early events of vascular
maturation, but may contribute to survival at later stages of
development.
Discussion
This study demonstrates for the ﬁrst time that SMC b-catenin
is essential for developmental vascular maturation. SMC
b-catenin deletion impairs artery formation with critical effects
on SMC proliferation and survival. While other signalling
pathways, including Notch38,39, sphingosine-1-phosphate40,41,
PDGFB/PDGFRb42–44 and TGF-b8,45–47 participate in vascular
maturation, the phenotype due to SMC b-catenin inactivation is
distinct in terms of timing, vessels affected and lack of effect on
cellular differentiation.
Mechanistically, we found that b-catenin inhibits p53 activity
in SMCs, and loss of this function impaired artery formation.
Interestingly, postnatal increase in p53 activity inhibits
angiogenesis48. Thus, repression of p53 activity appears
necessary for developmental vascular maturation and for
postnatal angiogenesis; our ﬁndings point to this as a key
function of SMC b-catenin during development.
This functional connection between b-catenin and p53 is
surprising. To our knowledge, such an interaction has not been
demonstrated in vascular biology; moreover, it contrasts with
interactions described in cancer, wherein b-catenin induces
p53 stability and activity through a tumour-suppressor
ARF-dependent effect49, or p53 downregulates b-catenin by
promoting its degradation50. While b-catenin-mediated
repression of p53 may be speciﬁc to SMCs, relevance of this
mechanism to other biological contexts has yet to be tested, and
could be of particular interest for stem cell biology51.
How b-catenin suppresses p53 function in SMCs is not fully
elucidated, but our ﬁndings offer important clues. With b-catenin
deﬁciency, p53 activity was higher, but its expression was
unchanged. Since p53 abundance is tightly regulated by several
mechanisms, many of which affect the ability of Mdm2 to
ubiquitinate p53 (ref. 4), this lack of change in p53 levels suggests
that b-catenin does not impinge on this complex system. In
addition, b-catenin loss did not decrease expression of Mdm2 or
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Mmd4; and pharmacologic and genetic inhibition of
Mdm2/Mdm4 did not increase p53 activity. Moreover, while
b-catenin loss increased p53 acetylation, inhibition of
Mdm2/Mdm4 did not. Thus, the mechanism leading to
increased p53 activity on b-catenin deletion in vascular SMCs
differs from that characterized by p53 accumulation and
inhibition of Mdm2/Mdm4 function4. Our observations suggest
that vascular SMCs in culture do not require Mdm2/Mdm4
function to repress p53 activity, but they do require b-catenin.
Consistent with this idea, adult SMC-selective inactivation of
Mdm4 has no repercussions, whereas Mdm2 SMC-selective
inactivation induces death of intestinal SMCs without evidence of
a vascular phenotype52; however, the low level of inactivation in
this study limits conclusions about the role of Mdm2 in SMC
biology in the adult vasculature. Whether Mdm2 and Mdm4
are required in vascular SMCs in vivo in particular during
development has yet to be fully tested.
Our studies with mutant Ctnnb1 alleles and inhibitors in
vascular SMCs suggest that b-catenin N-terminal interactions
and b-catenin/TCF interaction are dispensable to repress p53
activity, while C-terminal interactions are required. In particular,
b-catenin forms that can interact with CBP also prevent p53
acetylation, a modiﬁcation required for p53 activation30. In
addition to CBP, other proteins interact with the b-catenin
C-terminus10; while our ﬁndings with the ICG001 inhibitor are
consistent with disruption of a direct b-catenin–CBP interaction,
it is possible that other C-terminal interactors are involved
and that the linkage between b-catenin and CBP is indirect.
These additional factors participate in chromatin remodelling or
connect b-catenin with the transcription initiation or elongation
machinery; they are not b-catenin speciﬁc, and interact with
other coactivators and transcription factors including p53
(refs 53,54). Our studies with the Gal4BD-p53 chimeric protein
reveal that b-catenin C-terminal interactions are required to
repress p53 activity, independent of possible effects on DNA
binding. In this context, it may be that p53 activity depends on
recruitment of acetyltransferases and other coactivators necessary
for transcription, and that the presence of the b-catenin
C-terminus affects availability of acetyltransferases/coactivators
in the SMC nucleus; b-catenin loss may increase this
pool of acetyltransferases/coactivators and thereby potentiate
p53 acetylation and activity. Alternatively, mechanisms
involving altered expression of b-catenin–CBP-dependent, but
TCF-independent, target genes whose products impinge on p53
acetylation and activity are also possible.
Notably, we found that SMC b-catenin C-terminal interactions
are physiologically relevant for artery formation. Indeed,
C-terminal interactions are required, while N-terminal inter-
actions dispensable for arterial assembly; this is consistent with
our cell culture studies and with the idea that mammals have a
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less strict requirement for b-catenin N-terminal signalling
compared with Drosophila55.
Whereas Ctnnb1D164A as the only source of b-catenin protein
in SMCs fully restored artery formation, p53 loss in SMbCKO
embryos resulted in an important but partial recovery, suggesting
that b-catenin C-terminal interactions go beyond modulation of
p53 activity. Such p53-independent mechanisms might involve
b-catenin/TCF interaction and activation of b-catenin target
genes. Although cyclin D1 has been characterized as a direct
transcriptional target of b-catenin in studies using promoter-
reporter constructs56, the unexpected increase in cyclin D1
mRNA observed in b-catenin-deﬁcient SMCs is consistent with
an indirect linkage between b-catenin and cyclin D1 expression57,
and may be due in part to the higher fraction of b-catenin-
deﬁcient cells in the G0/G1 phase of the cell cycle, during which
SMC cyclin D1 levels are high58.
Our studies indicate the signiﬁcance of SMC b-catenin
signalling function in vivo during arterial wall formation;
however, relevant upstream regulators of this pathway remain
unknown. Wnt ligands, released in an autocrine or paracrine
(from endothelial cells or other sources) manner, might signal to
SMCs for b-catenin stabilization and nuclear translocation during
vascular maturation. This hypothesis remains to be tested.
SMC growth plays a pathogenic role in vascular disease59;
our studies suggest that inhibition of b-catenin C-terminal
interactions might serve as a therapeutic strategy. In addition, our
ﬁndings show that SMC b-catenin is essential for the formation of
multilayered arterial walls, which may be relevant for therapeutic
angiogenesis and tissue engineering60,61. Moreover, tumour
vasculature forms by angiogenesis and arterio-venogenesis62;
our ﬁndings raise the possibility that SMC b-catenin contributes
to formation and maturation of tumour vasculature by promoting
SMC investment.
In conclusion, we have demonstrated that SMC b-catenin is
essential for artery formation, in part by acting as a repressor of
p53 and thereby promoting cell proliferation and survival.
This novel role of b-catenin requires its signalling function, in
particular, its C-terminal interactions. In addition to elucidating a
critical function for b-catenin in development, these ﬁndings have
implications for therapeutic angiogenesis, tissue engineering,
tumour vascularization and vascular disease.
Methods
Mice. Tagln-Cre20, Ctnnb1ﬂox/ﬂox21 and Trp53ﬂox/ﬂox mice63 as well as
Ctnnb1D164A/WT, Ctnnb1DC/WT and Ctnnb1dm/WT mice32 have been described.
Tagln-Cre mice (STOCK Tg(Tagln-cre)1Her/J, (C57BL/6 SJL)F2) and
Ctnnb1ﬂox/ﬂox (B6.129-Ctnnb1tm2Kem/KnwJ) mice were obtained from the Jackson
Laboratory. Trp53ﬂox/ﬂox mice in a mixed C57BL/6 129 FVB background
(provided by Dr Liang Zhu, Albert Einstein College of Medicine) were crossed with
Ctnnb1ﬂox/ﬂox mice for four generations before use in experimental breeding, and
the Ctnnb1D164A/WT, Ctnnb1DC/WT and Ctnnb1dm/WT were kept on a C57BL/6
background. In general, test genotypes were compared with littermate controls.
Male and female 8–16–week-old mice were used as breeders for timed mating.
Embryos from E9.5 to E19.5 and 21-day-old pups, male and female, were studied.
Noontime of the day of detecting vaginal plugs was designated as E0.5. Mice and
embryos were genotyped using tail or yolk sac DNA, respectively, plus validated
PCR protocols (see references for each mouse line). All animals were housed in
pathogen-free conditions, the procedures followed the rules and regulations of the
AAALAC and were approved by the Institutional Animal Care and Use Committee
(IACUC) of Albert Einstein College of Medicine.
Histopathological and morphometric analysis. Embryos from E9.5 to E12.5
were dissected under a Stemi 2000-C stereomicroscope (Zeiss), ﬁxed overnight with
4% formaldehyde in phosphate buffer (Fisher Scientiﬁc, SF100-4), dehydrated
through an ethanol gradient, treated with xylene and embedded longitudinally
in parafﬁn. Cross-sections (5mm) were stained with hematoxylin and eosin.
Hematoxylin and eosin-stained cross-sections of hearts and arteries were
photographed with a digital microscope (COOLSCOPE, Nikon). Morphometric
analysis of PDAs and FDAs, heart and OT was performed using ImageJ software.
Total cross-sectional and vessel lumen areas were measured, with the distance
between the total area edge and lumen edge indicating wall thickness. The total
area of future left and right ventricles were measured, as well as the area of
compacted and trabeculated myocardium in each ventricle. The ratio of
myocardium area to total area was also calculated. The length of OT and OT wall
thickness were also measured, and the latter was expressed as a fraction of the
whole OT cross-section.
Immunohistochemistry. Tissue sections were deparafﬁnized and rehydrated,
endogenous peroxidase activity neutralized and antigens retrieved by boiling in
sodium citrate solution (Vector Labs H-3300). Sections were blocked in 2% bovine
serum albumin (BSA)/10% normal serum (same species of secondary antibody)
and avidin-blocking solution (Vector) in phosphate-buffered saline (PBS),
incubated with primary antibody in 2% BSA/10% normal serum and
biotin-blocking solution (Vector) in PBS, incubated with biotinylated secondary
antibody 1:500 (Vector), incubated with ABC (Vector PK-6100) or ABC-AP
reagent (Vector AK-5000), incubated with DAB/substrate/chromogen system
(Dako K3467; brown) or AP substrate kit I (Vector SK-5100 reagent, red) and
counterstained with hematoxylin (Vector H-3404). Speciﬁcity of staining was
conﬁrmed by omission of the primary antibody. Images were obtained using a
digital microscope (COOLSCOPE, Nikon). Primary antibodies used included
anti-b-catenin (Santa Cruz sc-7963, 1:250 dilution), anti-a-SMA (Sigma A2547,
1:200 dilution), anti-Sm22a (Abcam 14106, 1:500 dilution), anti-CD31 (Abcam
28364, 1:50 dilution) and anti-pHH3 (Cell Signaling 9701, 1:50 dilution).
Immunoﬂuorescence. Tissue sections were deparafﬁnized and rehydrated, and
antigen retrieval performed by boiling in sodium citrate solution (Vector Labs
H-3300). Tissues were blocked in 0.3% Triton X-100, 2% BSA and 5% normal
serum (same species as secondary antibody) in PBS; incubated with primary
antibody in blocking solution; incubated with ﬂuorochrome-conjugated secondary
antibodies (Molecular Probes) in blocking solution; and stained with DAPI
during mounting (FLUORO-GEL II, with DAPI, Electron Microscopy Sciences
#17985-50). Fluorescent signals were visualized with Axio Observer.Z1 microscope
(Zeiss). Subsequent image processing was performed with ImageJ. Speciﬁcity of
staining was conﬁrmed by omission of the primary antibody. Primary antibodies
used: anti-b-catenin (Santa Cruz sc-7963, 1:50 dilution), anti-a-SMA (Santa
Cruz sc-32351, 1:200 dilution), anti-cleaved Caspase-3 (Cell Signaling 9661, 1:50
dilution), anti-pHH3 (Cell Signaling 9701, 1:50 dilution), anti-Ki67 (Abcam 15580,
1:100 dilution), anti-Sm22a (Abcam 14106, 1:50 dilution) and anti-Bax (Abcam
32503, 1:50 dilution).
TUNEL assay. An in situ cell death detection kit with ﬂuorescein readout (Roche)
was used as per the manufacturer’s instructions. Brieﬂy, tissue sections were
deparafﬁnized and rehydrated, permeabilized by microwave irradiation in 0.1M
Citrate buffer (pH 6), labelled with TUNEL reaction mixture (label solution and
terminal transferase), and analysed by ﬂuorescence microscopy (Axio Observer.Z1
microscope, Zeiss). Sections incubated with label solution without transferase
were used as negative controls. Sections incubated with DNase I before labelling
procedures served as positive controls.
Mouse aortic SMCs. Primary SMCs were obtained from 5 to 6-week-old
Ctnnb1ﬂox/ﬂox and Ctnnb1WT/WT mouse aortas using collagenase-elastase
digestion64 as follows: aortas were collected from the aortic arch to the iliac
bifurcation, rinsed with cold serum-free DMEM with antibiotics, moved to the cell
culture hood, stripped of adventitia, minced with scissors and digested with
Collagenase 0.5mgml 1 (Sigma type I, C-0130) and Elastase 0.125 mgml 1
(Sigma type III, E-0127) in serum-free DMEM with antibiotics at 37 C until most
cells were in suspension; then, enzymes were inactivated by adding DMEM with
serum, and the cell suspension was recovered and centrifuged at 400g for 5min,
the SMC pellet was washed with complete medium, and SMCs plated in
Fibronectin-coated dishes. Mouse aortic SMCs were maintained in DMEM
(Invitrogen) containing 20% fetal bovine serum (FBS, HyClone), 100Uml 1
penicillin, 100 mgml 1 streptomycin and 1% L-glutamine, and subcultured weekly.
Passages 2 or 3 were used for transduction with GFP- or Cre-expressing adenovirus
(Ad5.CMV-GFP or Ad5.CMV-Cre) to obtain control or cells lacking b-catenin,
respectively, and passages 4 to 8 were used for experiments. To evaluate cell
population growth, 0.2 105 cells of each group were plated in 35mm dishes in
triplicate for every time point, allowed to seed overnight, serum-starved for 48 h
and then stimulated with and maintained in 20% FBS, and counted every 2 days
using trypan blue exclusion and a hemocytometer. To evaluate cell population
decline, 3 105 cells of each group were plated in 35mm dishes in triplicate for
every time point, allowed to seed overnight, maintained under serum starvation
and counted every day.
Western blotting. Whole-cell protein lysates were extracted from SMCs using
RIPA buffer (50mM Tris-HCL pH 7.4, 1% NP40, 0.5% sodium deoxycholate, 0.1%
SDS, 1mM EDTA, 150mM NaCl) with protease inhibitors (Complete, Roche).
Protein concentrations were measured by a BCA protein assay kit (Pierce) and
equal amounts of protein samples were loaded (20–60 mg), separated by 10%
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms12389 ARTICLE
NATURE COMMUNICATIONS | 7:12389 | DOI: 10.1038/ncomms12389 |www.nature.com/naturecommunications 11
polyacrylamide gel electrophoresis and blotted onto PVDF membranes (Immobi-
lon-P, Millipore). After blocking in TBST (Tris pH 8.0, NaCl 150mM, 0.1% Tween
20) plus 4% (w/v) non-fat milk or BSA, blots were incubated at 4 C overnight with
primary antibodies. Signals were detected with horseradish peroxidase-conjugated
secondary antibody and chemiluminescence (ECL, GE Healtcare). Equivalent
protein loading was tested with anti-GAPDH (Santa Cruz, sc-25778, 1:5,000
dilution). Primary antibodies used: anti-b-catenin (Santa Cruz sc-7963, 1:500
dilution), anti-a-SMA (Sigma A2547, 1:5,000 dilution), anti-Sm22a (Abcam 14106,
1:10,000 dilution), anti-p53 (Santa Cruz sc-6243, 1:500 dilution), anti-MDM2
(Santa Cruz sc-965, 1:200 dilution), anti-MDMX (Santa Cruz sc-74468, 1:200
dilution), anti-Lamin A/C (Santa Cruz sc-6215, 1:200 dilution) and anti-CBP
(Santa Cruz sc-369, 1:100 dilution). All uncropped blots can be found in
Supplementary Fig. 8.
Cell cycle analysis. SMCs (1 106 cells) were incubated with 20mM BrdU for 1 h,
collected and ﬁxed with ice-cold 70% ethanol while vortexing, then washed
and incubated with 2N HCl/0.5% Triton X-100, resuspended in 0.1M sodium
tetraborate and resuspended in 0.5% Tween 20/1% BSA/PBS. In all, 20 ml of
Anti-BrdU-FITC (Cat. No. 347583) were added and cells incubated for 30min at
room temperature, then cells were washed and resuspended in 0.5ml of PBS
containing 10mgml 1 RNase A and 10 mgml 1 of propidium iodide for
ﬂuorescence-activated cell-sorting analysis in the Flow Cytometry Core Facility
at Albert Einstein College of Medicine. Data were analysed with FlowJo 8.7
(FlowJo, LLC).
Survival assay. SMCs (5 104) were plated on a 22 22mm coverslip in
triplicate for each condition, allowed to become a subconﬂuent monolayer and
then treated with 20 or 0% FBS for 48 h. Dead and live cells were distinguished by
adding 150 ml of combined LIVE/DEAD assay reagents (2 mM Calcein AM and
4 mM ethidium homodimer-1) (L-3224, Life Techologies) to each coverslip.
The percentage of dead cells for each coverslip was determined as the mean of
(100 dead/(liveþ dead)) of 16 randomly selected epiﬂuorescent photomicro-
graphic ﬁelds (Axio Observer.Z1 microscope, Zeiss). ImageJ software was used to
count cells.
Immunocytochemistry. SMCs were plated in chamber slides (BD Bioscience) 24 h
before staining, washed with PBS and ﬁxed with cold methanol, blocked with 3%
normal goat serum/1% BSA/0.01% Triton X-100 in PBS, and incubated with
anti-b-catenin (Santa Cruz sc-7963, 1:100 dilution), anti-CBP (Santa Cruz sc-369,
1:100 dilution) or anti-Sm22a (Abcam 14106, 1:200 dilution). Speciﬁc staining was
identiﬁed with Alexa546 goat anti-mouse and Alexa488 goat anti-rabbit IgG
(Molecular Probes). Samples were counterstained with DAPI and signals visualized
with Axio Observer.Z1 microscope (Zeiss). Subsequent image processing was
performed with ImageJ. Routine control experiments included omission of the
primary antibodies.
Transwell migration assay. A 6.5mm Transwell system with 8.0 mm pore
polyester membrane insert (Corning 3464) was used. SMCs were serum-starved for
24 h, collected and plated at 5 104 cells per insert (upper chamber) in DMEM,
as described before, containing either 0.2% or 20% FBS. The inserts were place into
wells (lower chamber) containing either 0.2% or 20% FBS. After 8 h, cells
remaining on top of the membrane were removed and cells that reached the
bottom ﬁxed and stained with Hema3 (Stat Pack Cat #123-869). The number of
cells per high-power ﬁeld ( 200) was counted in 10 random ﬁelds per membrane.
Triplicates for every genotype and condition were used every time.
Luciferase assays. Vascular SMCs (5 104 per well) were electroporated with
pCMV-b-gal (transfection control) and with pG13-Luc (p53 activity-luciferase
reporter, Addgene), pFR-Luc (Stratagene), M50 super 8 TOPﬂash (b-catenin/
TCF activity reporter, Addgene) or M51 Super 8 FOPFlash (TOPﬂash mutant,
Addgene). When indicated, pCMV-p53, pCMV-BD-p53, pcDNA3-b-cateninS33Y
(constitutively active b-catenin), pcDNA3-b-cateninS33Y-dm, pcDNA3-b-
cateninS33Y-DC, pcDNA3-b-cateninS33Y-D164A, pCFC-X2 (Mdm2-expressing
vector) or empty vector were also included in the electroporation protocol. Vectors
expressing wild-type and mutant b-cateninS33Y have been previously validated32, as
well as the Mdm2-expressing vector pCFC-X2 (ref. 65, kindly provided by M. Oren).
To generate the chimeric protein Gal4BD-p53, mouse p53 cDNA was generated by
PCR from a mouse cDNA sample with primers containing HindIII and NotI sites
to facilitate cloning (F 50-gatcaagcttgactgccatggaggagtc-30 and R 50-gagatcgcggccg
ctagtcagtctgagt-30), and the product was subcloned into the pCMV-BD vector
(Stratagene). The electroporation was performed using the Neon transfection
system (Invitrogen). Electroporated cells were plated in antibiotic-free medium in a
24-well plate for 24 h and then switched to regular medium. Triplicates for every
group and condition were used every time. Cell lysates were collected 72 h after
electroporation and luciferase activity was determined using the Glo-lysis buffer
system (Promega) and the Synergy 2 Microplate Reader (BioTek). Luciferase
activities were normalized to b-galactosidase activity for each well to control for
transfection efﬁciency. When indicated, cells were treated as follows: (i) with
validated doses of XAV939 (Cayman Chemical 13596; 1 or 10 mM), RO-5963
(Calbiochem 44153; 5, 10 or 20 mM), PKF118-310 (Sigma K4394; 0.7 mM)
or vehicle; (ii) serum-starved 24 h before collecting; (iii) transfected with
Mdm2/Mdm4 or both, or control Ambion Silencer Select Pre-designed siRNAs
using X-tremGENE siRNA transfection reagent (Roche 04476093001).
Real-time PCR. Total RNA was isolated from SMCs by homogenization in TRIzol
(Invitrogen), treated with DNase I (1U ml 1, Promega) and used for ﬁrst-strand
cDNA synthesis (SuperScriptIII, Invitrogen). Quantitative PCR was performed
using a SYBR Green qPCR kit (Stratagene) and Mx3000P Real-Time PCR system
(Stratagene). mRNA levels were normalized to Rps13 and expressed as relative
values in comparison with the speciﬁc control group using the comparative DDCt
method (User Bulletin #2, ABI Prism 7700, Applied Biosystems). Primer sequences
were as follows: Axin2 (F 50-gagagtgagcggcagagc-30 , R 50-cggctgactcgttctcct-30), Bax
(F 50-gtgagcggctgcttgtct-30 , R 50-ggtcccgaagtaggagagga-30), Bcl2l1 (F 50-tgaccacct
agagccttgga-30 , R 50-tgttcccgtagagatccacaa-30), Ccnd1 (F 50-gagattgtgccatccatgc-30 ,
R 50-ctcctcttcgcacttctgct-30), Cdkn1a (F 50-aacatctcagggccgaaa-30 , R 50-tgcgcttggagtg
atagaaa-30), Rps13 (F 50-tgctcccacctaattggaaa-30 , R 50-cttgtgcacacaacagcattt-30) and
Trp53 (F 50-acgcttctccgaagactgg-30 , R 50-agggagctcgaggctgata-30).
Acetylation of p53. Evaluation of p53 acetylation in SMCs was done by a
PathScan Acetylated p53 Sandwich ELISA kit (Cell Signaling 7236C), following
manufacturer instructions. Brieﬂy, total cell lysates were obtained, sonicated and
protein concentration measured. Then, 100 ml of each sample containing equal
amount of protein was added to a microwell coated with a p53 mouse monoclonal
antibody and incubated at 4 C overnight. The microwells were extensively washed,
and an acetylated-lysine rabbit monoclonal antibody added for 1 h at 37 C. After
washing, an anti-rabbit horseradish peroxidase-linked antibody was added for 0.5 h
at 37 C. After washing, 100 ml of TMB substrate was added for 10min at 37 C.
Then, 100ml of STOP solution was added and absorbance at 450 nm read in a
Synergy 2 Microplate Reader (BioTek). The magnitude of the absorbance is
proportional to the quantity of acetylated p53. Triplicates for every genotype and
condition were used every time. When indicated, cells were treated with 10 mM
RO5963 (Calbiochem 44153), 50 mM of ICG001 (SelleckBio S2662) or vehicle
(DMSO); or transfected with CBP siRNA (Santa Cruz sc-29243) or control siRNA
(Santa Cruz sc-44231) using X-tremGENE siRNA transfection reagent (Roche
04476093001).
Isolation of nuclear fraction. Control mouse aortic SMCs were collected by
trypsinization, washed with ice-cold PBS and collected by gentle centrifugation.
Isolation of cellular fractions was done using the Qproteome nuclear protein kit
(QIAGEN 37582), following manufacturer’s instructions. Brieﬂy, 5 106 SMCs
were resuspended in hypotonic Lysis buffer NL. Then detergent was added and
cells were vortexed to rupture the plasma membrane. Centrifugation was used to
separate the cytosolic fraction (supernatant) from nuclei (pellet). The nuclear pellet
was washed and incubated in a high-salt buffer. Centrifugation was used to
separate the nucleic-acid-binding proteins (supernatant) from the nuclear debris
(including genomic DNA). Extraction of the ‘insoluble’ nuclear proteins was done
by incubating nuclear debris with a buffer containing Benzonase, which digests
DNA and releases proteins intimately associated with DNA.
Statistics. Comparisons between two groups were evaluated by two-tailed t-test,
and between more than two groups by one-way or two-way ANOVA (analysis of
variance) followed by post hoc test when appropriate. Analysis of phenotypic
categories and comparison of observed versus expected genotype frequencies was
done by w2-test or Fisher’s exact test. Signiﬁcance was accepted for values of
Po0.05. All in vitro experiments were replicated at least three independent times.
For developmental animal studies, no statistical method was used to predetermine
sample size. In general, breeding strategies were designed to produce embryos with
the genotypes of interest and controls within the same litter—thus littermates were
compared—and no randomization was necessary to allocate animals in experi-
mental groups. No embryos were excluded from the analysis, and investigators
were not blinded.
Data availability. The authors declare that all data supporting the ﬁndings of this
study are available within the article and its Supplementary Information ﬁles or
from the corresponding author on reasonable request.
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